{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:20:08Z","timestamp":1758050408603,"version":"3.44.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.bulcan.2020.01.014","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T19:08:12Z","timestamp":1584126492000},"page":"519-520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prot\u00e9inurie dans le my\u00e9lome\u00a0: attention \u00e0 la iatrog\u00e9nie"],"prefix":"10.1016","volume":"107","author":[{"given":"Manon","family":"Sapet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovic","family":"Fouillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Daguenet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blandine","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Guyotat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Le Jeune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2020.01.014_bib0055","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-10-459883","article-title":"Carfilzomib","volume":"121","author":"Kortuem","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.01.014_bib0060","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3\u00a0trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2020.01.014_bib0065","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1038\/bcj.2017.31","article-title":"Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment","volume":"7","author":"Dimopoulos","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bulcan.2020.01.014_bib0070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2174\/187152909787581318","article-title":"Thrombotic microangiopathies: towards a pathophysiology-based classification","volume":"9","author":"Coppo","year":"2009","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"10.1016\/j.bulcan.2020.01.014_bib0075","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.nephro.2017.01.023","article-title":"Thrombotic microangiopathy and cancer","volume":"13","author":"Kheder El-Fekih","year":"2017","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.bulcan.2020.01.014_bib0080","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/jca.21371","article-title":"Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange","volume":"30","author":"Sullivan","year":"2015","journal-title":"J Clin Apheresis"},{"key":"10.1016\/j.bulcan.2020.01.014_bib0085","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1471-2369-15-156","article-title":"Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma","volume":"15","author":"Hobeika","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.bulcan.2020.01.014_bib0090","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24447","article-title":"Proteasome inhibitor associated thrombotic microangiopathy","volume":"91","author":"Yui","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2020.01.014_bib0095","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.transci.2016.03.002","article-title":"Carfilzomib: a cause of drug associated thrombotic microangiopathy","volume":"54","author":"Qaqish","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.bulcan.2020.01.014_bib0050","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s004670050189","article-title":"Development of focal segmental sclerosis and hyalinosis in hemolytic uremic syndrome","volume":"10","author":"Caletti","year":"1996","journal-title":"Pediatr Nephrol Berl Ger"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120301314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120301314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:33:17Z","timestamp":1757791997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455120301314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0007455120301314"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.01.014","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prot\u00e9inurie dans le my\u00e9lome\u00a0: attention \u00e0 la iatrog\u00e9nie","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}